Granted Patent B2

US 12,478,686 · App. 17/297,830 · Granted Nov 25, 2025

Inventors: Pavel Strop (San Mateo, CA); Chetana Rao-Naik (Walnut Creek, CA); Xiaodi Deng (San Mateo, CA); Paul O. Sheppard (Granite Falls, WA); Sean Matthew WEST (Union City, CA); Jason Michael Hogan (Palo Alto, CA); Sayumi Yamazoe (Mountain View, CA)

Assignee: BRISTOL-MYERS SQUIBB COMPANY

A61K47/6803A61K47/6851A61K47/6889C07K16/30C07K2317/522C07K2317/524C07K2317/526C07K2317/92

Abstract

Claims (33)

1 . A full-length IgG antibody, having a modification selected from the group consisting of:

(i) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO: 9 or SEQ ID NO: 10;

(ii) replacement of the amino acids at EU 160 through 164 of a heavy chain with the amino acids of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO:17;

(iii) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO: 18, SEQ ID NO: 19, or NO: 20;

(iv) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24;

(v) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 or SEQ NO: 28;

(vi) replacement of the amino acids at EU 280 through 284 of a heavy chain with the amino acids of SEQ ID NO:29, SEQ ID NO:30, or SEQ ID NO:31;

(vii) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO: 43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103;

(viii) replacement of the amino acids at EU 314 through 319 of a heavy chain with the amino acids of SEQ ID NO:48, SEQ ID NO:49 or SEQ ID NO:50;

(ix) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53;

(x) replacement of the amino acids at EU 358 through 362 of a heavy chain with the amino acids of SEQ ID NO:54 or SEQ ID NO:55;

(xi) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO:63 or SEQ ID NO:64;

(xii) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO: 65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO:69;

(xiii) replacement of the amino acids at EU 122 through 126 of a light chain with the amino acids of SEQ ID NO:70, SEQ ID NO:71, or SEQ ID NO:72;

(xiv) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73, SEQ ID NO:74, or SEQ ID NO:75;

(xv) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO:76, SEQ ID NO: 77, SEQ ID NO:78, SEQ ID NO: 79, SEQ ID NO:81, or SEQ ID NO:82;

(xvi) replacement of the amino acids at EU 182 through 190 of a light chain with the amino acids of SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, or SEQ ID NO:87; and

(xvii) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO:92, SEQ ID NO: 93, SEQ ID NO:94, SEQ ID NO: 95, or SEQ ID NO:96.

2 . The antibody of claim 1 , which is an IgG1 antibody.

3 . The antibody of claim 2 , wherein the modification is in a heavy chain.

4 . The antibody of claim 2 , wherein the modification is selected from the group consisting of:

(I) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:9 or SEQ ID NO: 10;

(II) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO: 18;

(III) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22;

(IV) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:27 or SEQ ID NO:28;

(V) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO: 40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103;

(VI) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO: 51, SEQ ID NO:52 or SEQ ID NO:53;

(VII) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:57, SEQ ID NO:58, or SEQ ID NO:63;

(VIII) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO:66 or SEQ ID NO:68;

(IX) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73 or SEQ ID NO:75;

(X) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO: 78 or SEQ ID NO:82; and

(XI) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO: 92, SEQ ID NO: 93 or SEQ ID NO:94.

5 . The antibody of claim 2 , wherein the replacement sequence comprises the tripeptide -VLQ-.

Assignments (1)

Continuity (2)

References Cited (32)